使用免疫生物制剂评估银屑病患者的肾功能。
Evaluation of renal function in patients with psoriasis using immunobiologicals.
作者信息
Melgaço Sarah Suyanne Carvalho, Silva Geraldo Bezerra da, Dantas Amanda Maria Menezes, Vasconcelos Ana Mirella Arcanjo, Siqueira Verônica Riquet de, Vieira Ana Patrícia Freitas, Daher Elizabeth de Francesco
机构信息
Fortaleza(CE),Brazil.
出版信息
An Bras Dermatol. 2013 Jul-Aug;88(4):667-9. doi: 10.1590/abd1806-4841.20132035.
Abstract
The aim of this study was to evaluate renal function in patients with psoriasis using immunobiologicals. A prospective study was conducted with 15 patients with confirmed diagnosis of psoriasis who were starting to use immunobiologicals. The mean age was 41 ± 11 years, with 60% females. The mean time of disease was 11 ± 6.6 years. Significant changes in creatinine and creatinine clearance were not observed in the course of the study. There was an increase in transaminases and a decrease in magnesium levels.
摘要
本研究的目的是评估使用免疫生物制剂的银屑病患者的肾功能。对15例确诊为银屑病且开始使用免疫生物制剂的患者进行了一项前瞻性研究。平均年龄为41±11岁，女性占60%。疾病平均病程为11±6.6年。在研究过程中未观察到肌酐和肌酐清除率的显著变化。转氨酶升高，镁水平降低。
相似文献
1
Evaluation of renal function in patients with psoriasis using immunobiologicals.使用免疫生物制剂评估银屑病患者的肾功能。
An Bras Dermatol. 2013 Jul-Aug;88(4):667-9. doi: 10.1590/abd1806-4841.20132035.
2
Biologicals in the treatment of psoriasis.生物制剂在银屑病治疗中的应用
Curr Opin Investig Drugs. 2007 Nov;8(11):939-46.
3
Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients.在日常临床实践中，生物疗法治疗银屑病的耐受性和安全性：对 103 例意大利患者的研究。
Acta Derm Venereol. 2011 Jan;91(1):44-9. doi: 10.2340/00015555-0959.
4
[Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
Actas Dermosifiliogr. 2010 Mar;101(2):156-63.
5
Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.从依那西普转换至阿达木单抗是有效且安全的：结果显示在 30 例对依那西普原发性失效、继发性失效或不耐受的银屑病患者中。
Br J Dermatol. 2010 Oct;163(4):838-46. doi: 10.1111/j.1365-2133.2010.09950.x. Epub 2010 Sep 2.
6
Experience with biologics for psoriasis in daily practice: switching is worth a try.
Br J Dermatol. 2009 Oct;161(4):948-51. doi: 10.1111/j.1365-2133.2009.09384.x. Epub 2009 Aug 7.
7
Biologic therapy in psoriasis: perspectives on associated risks and patient management.生物制剂治疗银屑病：相关风险及患者管理的观点。
J Cutan Med Surg. 2012 May-Jun;16(3):153-68. doi: 10.1177/120347541201600305.
8
Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, Infliximab and Adalimumab.生物治疗下患有甲银屑病的患者的甲真菌病：比较依那西普、英夫利昔单抗和阿达木单抗的随机、前瞻性开放标签研究。
Expert Opin Biol Ther. 2013 May;13(5):625-9. doi: 10.1517/14712598.2013.783561. Epub 2013 Mar 26.
9
The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.英夫利昔单抗治疗依那西普应答不足的斑块状银屑病患者的疗效和安全性：一项前瞻性、多中心、开放性研究的结果。
J Am Acad Dermatol. 2012 Oct;67(4):642-50. doi: 10.1016/j.jaad.2011.10.020. Epub 2011 Dec 9.
10
Biologic agents in the treatment of psoriasis.生物制剂在银屑病治疗中的应用
Recent Pat Inflamm Allergy Drug Discov. 2007 Nov;1(3):193-217. doi: 10.2174/187221307782418919.
引用本文的文献
1
Kidney involvement in psoriasis: a case-control study from China.银屑病的肾脏受累：一项来自中国的病例对照研究。
Int Urol Nephrol. 2017 Nov;49(11):1999-2003. doi: 10.1007/s11255-017-1692-x. Epub 2017 Sep 22.
2
Kidney disease and psoriasis: novel evidences beyond old concepts.肾病与银屑病：超越旧有观念的新证据。
Clin Rheumatol. 2016 Feb;35(2):297-302. doi: 10.1007/s10067-015-3126-4. Epub 2015 Nov 28.
本文引用的文献
1
[Psoriasis in the era of biologics].生物制剂时代的银屑病
Acta Med Port. 2010 May-Jun;23(3):493-8. Epub 2010 Jun 14.
2
Extracapillary glomerulonephritis during etanercept treatment for juvenile psoriatic arthritis.依那西普治疗幼年特发性关节炎时并发血管外肾小球肾炎。
Clin Exp Rheumatol. 2010 Jan-Feb;28(1):91-3.
3
[Off-label use of biologic agents in the treatment of dermatosis, Part 1: infliximab and adalimumab].[生物制剂在皮肤病治疗中的超说明书用药，第1部分：英夫利昔单抗和阿达木单抗]
Actas Dermosifiliogr. 2007 Dec;98(10):657-78.
4
Potential complications associated with the use of biologic agents for psoriasis.使用生物制剂治疗银屑病相关的潜在并发症。
Dermatol Clin. 2007 Apr;25(2):207-13, vii. doi: 10.1016/j.det.2007.01.010.
5
Biologic agents in psoriasis.银屑病中的生物制剂
Australas J Dermatol. 2006 Nov;47(4):217-29; quiz 229-30. doi: 10.1111/j.1440-0960.2006.00286.x.
6
Infliximab and nephrotic syndrome.英夫利昔单抗与肾病综合征。
Nephrol Dial Transplant. 2005 Dec;20(12):2824-6. doi: 10.1093/ndt/gfi180. Epub 2005 Oct 4.
7
Overview of biologic agents in medicine and dermatology.医学与皮肤病学中的生物制剂概述。
Semin Cutan Med Surg. 2005 Mar;24(1):2-9. doi: 10.1016/j.sder.2005.01.007.
8
Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.类风湿关节炎抗TNF-α治疗期间肾小球肾炎的发生
Nephrol Dial Transplant. 2005 Jul;20(7):1400-6. doi: 10.1093/ndt/gfh832. Epub 2005 Apr 19.
9
Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.与用于治疗类风湿关节炎的改善病情抗风湿药相关的肾毒性。
Semin Arthritis Rheum. 2000 Dec;30(3):196-208. doi: 10.1053/sarh.2000.16641.
Zotero 插件